Longboard Pharmaceuticals shares are trading higher after the company announced it received rare pediatric disease and orphan drug designations from the FDA for bexicaserin (LP352) in Dravet syndrome.
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals' shares rose following the FDA's rare pediatric disease and orphan drug designations for its drug bexicaserin (LP352) targeting Dravet syndrome.
September 19, 2024 | 7:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longboard Pharmaceuticals' stock increased due to FDA's rare pediatric disease and orphan drug designations for bexicaserin (LP352) in Dravet syndrome.
The FDA's designations are significant milestones that can lead to market exclusivity and potential financial incentives, positively impacting Longboard Pharmaceuticals' stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100